SG
HOWL icon

StoneX Group’s Werewolf Therapeutics HOWL Stock Holding History

StoneX Group’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9K Buy
+20,000
New +$12.2K ﹤0.01% 1369
2026
Q1 		– Sell
-10,511
Closed -$6.66K – 1062
2025
Q4 		$6.66K Buy
+10,511
New +$12.8K ﹤0.01% 1019

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

StoneX Group's HOWL Position: Q2 2026 in Review

StoneX Group opened a new position in Werewolf Therapeutics (HOWL) in Q2 2026: 20,000 shares worth $9K. The stake represents ﹤0.01% of the portfolio and ranks #1369 among its holdings. This is a return to the name: StoneX Group previously reported a position in HOWL as recently as Q4 2025.

StoneX Group first reported a position in HOWL in Q4 2025 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • StoneX Group held 20,000 shares of Werewolf Therapeutics worth $9K as of Q2 2026.
  • Werewolf Therapeutics was a new StoneX Group position in Q2 2026.
  • Werewolf Therapeutics made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1369 holding.
  • StoneX Group first reported a position in Werewolf Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.